Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need.
Products, services, technology
AGAMREE® (vamorolone), a dissociative steroid with a novel mode of action, is Santhera’s lead product for the treatment of Duchenne muscular dystrophy (DMD). AGAMREE is approved in the U.S., EU, UK, China, Hong Kong and Canada. Santhera holds an exclusive worldwide license from ReveraGen.
Cooperation possibilities
Vamorolone represents a platform-type pipeline molecule, with potential for out-licensing or development in a range of additional indications beyond its prime indication Duchenne muscular dystrophy (DMD), respectively, in collaboration with partners.
- http://www.santhera.com
- +41 61 906 89 50
- Send an email
- Catherine Isted
